Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Boralex Inc
T.BLX
Alternate Symbol(s):
BRLXF
Utilities
Utilities - Independent Power Producers
Boralex Inc. is a renewable energy company specializing in four sectors of activity: wind, solar, hydroelectricity and storage. It is engaged in the development, construction, and operation of renewable energy power facilities. It develops, builds and operates power generating and storage facilities in Canada, France, the United States and the United Kingdom. It is developing a portfolio of more than 6.8 gigawatts (GW) in wind, solar projects and storage projects. It also provides management and maintenance services to certain joint ventures and associates. In addition, it has projects under construction or ready-to-build, representing an additional 264 megawatts (MW) of power and a portfolio of secured projects amounting to 587 MW. It is an independent producer of onshore wind power and has facilities in the United States and development projects in the United Kingdom. A major part of its installed capacity is accounted for by wind energy. It also owns the Sallachy Wind Farm project.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
TSX:BLX - Post by User
Boralex Inc
> Recent sell-off
<< Previous
Bullboard Posts
Next >>
(1267)
•••
Vega1357
X
View Profile
View Bullboard History
Comment by
Vega1357
on Aug 11, 2021 12:25pm
100 Views
Post# 33685191
RE:Recent sell-off
RE:Recent sell-off
According to Marketbeat, the average target price for BLX based on the analysts they follow is $47.02 giving it a 29% upside potential.
Comment on this Post
<< Previous
Bullboard Posts
Next >>
Eminent acquires promising Nevada gold project
BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide
NervGen Pharma: Proof that NVG-291 works?
Invest wiser with BMO's InvestorLine Platform features
A potential breakthrough in spinal cord and optic nerve injury treatment
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
Growth Rocket 2025 – Why dynaCERT is in the Spotlight
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product
Do you want to stay ahead of the markets? See how DealRoom can help.
Debt-Free Cannabis Company Set for Next Stage of Growth